Research ArticleClinical Investigation
First-in-Humans Evaluation of 18F-SMBT-1, a Novel 18F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis
Victor L. Villemagne, Ryuichi Harada, Vincent Doré, Shozo Furumoto, Rachel Mulligan, Yukitsuka Kudo, Samantha Burnham, Natasha Krishnadas, Svetlana Bozinovski, Kun Huang, Brian J. Lopresti, Kazuhiko Yanai, Christopher C. Rowe and Nobuyuki Okamura
Journal of Nuclear Medicine October 2022, 63 (10) 1551-1559; DOI: https://doi.org/10.2967/jnumed.121.263254
Victor L. Villemagne
1Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania;
2Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia;
Ryuichi Harada
3Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan;
4Institute of Development of Aging and Cancer, Tohoku University, Sendai, Japan;
Vincent Doré
2Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia;
5CSIRO Health and Biosecurity Flagship: Australian e-Health Research Centre, Melbourne, Victoria, Australia;
Shozo Furumoto
6Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan;
Rachel Mulligan
2Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia;
Yukitsuka Kudo
4Institute of Development of Aging and Cancer, Tohoku University, Sendai, Japan;
Samantha Burnham
5CSIRO Health and Biosecurity Flagship: Australian e-Health Research Centre, Melbourne, Victoria, Australia;
Natasha Krishnadas
2Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia;
Svetlana Bozinovski
2Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia;
Kun Huang
2Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia;
Brian J. Lopresti
7Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania;
Kazuhiko Yanai
3Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan;
Christopher C. Rowe
2Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia;
8Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia;
9Australian Dementia Network, Melbourne, Victoria, Australia; and
Nobuyuki Okamura
10Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 10
October 1, 2022
First-in-Humans Evaluation of 18F-SMBT-1, a Novel 18F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis
Victor L. Villemagne, Ryuichi Harada, Vincent Doré, Shozo Furumoto, Rachel Mulligan, Yukitsuka Kudo, Samantha Burnham, Natasha Krishnadas, Svetlana Bozinovski, Kun Huang, Brian J. Lopresti, Kazuhiko Yanai, Christopher C. Rowe, Nobuyuki Okamura
Journal of Nuclear Medicine Oct 2022, 63 (10) 1551-1559; DOI: 10.2967/jnumed.121.263254
First-in-Humans Evaluation of 18F-SMBT-1, a Novel 18F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis
Victor L. Villemagne, Ryuichi Harada, Vincent Doré, Shozo Furumoto, Rachel Mulligan, Yukitsuka Kudo, Samantha Burnham, Natasha Krishnadas, Svetlana Bozinovski, Kun Huang, Brian J. Lopresti, Kazuhiko Yanai, Christopher C. Rowe, Nobuyuki Okamura
Journal of Nuclear Medicine Oct 2022, 63 (10) 1551-1559; DOI: 10.2967/jnumed.121.263254